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Abstract
Background and Purpose—Individuals with migraine are at higher risk for 
stroke, but the mechanism has not been established. Based upon the 
association between migraine, and intracardiac right-to-left shunt (RLS), it has
been proposed that stroke in migraineurs could be due to a paradoxical 
embolus passing through a patent foramen ovale (PFO) or pulmonary AVM. 
The aim of this study was to determine the prevalence of PFO with RLS in 
patients who presented with cryptogenic stroke and had a history of migraine.
Methods—Patients between 18 and 60 years old who presented with an 
ischemic stroke were characterized based on ASCOD phenotyping. A 
migraine diagnosis was identified by reviewing physician notes and frequent
aura was defined if present in at least 50% of attacks. A PFO with RLS 
diagnosis was identified by the presence of a positive bubble contrast study 
with either transcranial Doppler, transthoracic or transesophageal 
echocardiography.
Results—Of the 712 patients who presented with ischemic stroke, 127 (18%)
were diagnosed as cryptogenic; 68 patients had adequate testing for PFO and
a documented migraine history. The prevalence of PFO in patients with 
cryptogenic stroke without migraine was elevated (59%) compared with the 
general population (18%). Patients with both cryptogenic stroke and migraine 
had a higher prevalence of PFO (79%). In patients with cryptogenic stroke 
who had migraine with
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frequent aura, the prevalence of PFO was 93%. Only five patients (4%) had a
history compatible with migrainous infarction.
Conclusions—In patients with cryptogenic stroke who have migraine, there is
a high prevalence (79%) of PFO with RLS. The timing of the stroke in 
migraineurs is usually not related to a migraine attack. These observations are
consistent with the hypothesis that the mechanism of stroke in migraineurs is 
most likely due to a paradoxical embolus. Future cryptogenic stroke 
classification schemes should consider including PFO as a separate etiologic 
category.
Keywords
stroke; migraine with aura; migraine without aura; patent foramen ovale; shunt
Subject Terms (Journal List)
Cerebrovascular Disease/Stroke; Ischemic Stroke; Embolism
INTRODUCTION
Epidemiologic studies reveal that people who have a history of migraine 
headache with aura have a risk of developing a stroke that is 2.3 times 
higher than in people without migraine (1). This risk increases 
substantially in patients who smoke and/or use birth control pills, with an
odds ratio for stroke as high as 13.9 (95% confidence interval 5.5 – 35.1) 
(2–4).
Based upon the association between migraine, particularly migraine 
with aura, and intracardiac right-to-left shunt (RLS), it has been 
proposed that stroke in migraineurs could be due to a paradoxical 
embolus passing through a patent foramen ovale (PFO) or pulmonary 
arteriovenous malformation (PAVM) (5).
The initial theory to explain the higher risk of stroke in migraineurs 
asserted that migraine was a "vascular headache" resulting from 
heightened cerebral arterial vasoreactivity (6–8).Ifthe cerebral arterial 
spasm was excessive, then persistent ischemia would result in a focal 
stroke. Although migraine attacks may be associated with cerebral 
oligemia, the reduction in blood flow (about 25%) rarely reaches the 
threshold for ischemia (9), and migrainous infarction is very uncommon 
(10). Migraine is no longer considered to be primarily a “vascular 
headache”, but rather it is a disorder of nervous system excitability 
where vascular alteration may occur, but is not the predominant 
mechanism responsible for migraine symptoms. The hypothesis for this 
study was that the majority of patients who presented with cryptogenic 
stroke and had a history of migraine, would also have a PFO withRLS.
METHODS
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The authors declare that all supporting data are available within the 
article. Approval for this review study was granted from the UCLA 
Institutional Review Board (IRB). Informed consent was waived by the 
IRB. Patients between 18 and 60 years old who were diagnosed with 
stroke and came to the UCLA Comprehensive Stroke Center from January 
1, 2008 to November 1, 2017 were identified. Cases of ischemic stroke 
were reviewed and clinically categorized based on ASCOD phenotyping 
by the neurology evaluation in the medical
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records. ASCOD phenotyping categorizes the most likely etiology of the 
ischemic stroke as either A: atherosclerosis; S: small-vessel disease; C: 
cardiac pathology (other than PFO); O: other causes; D: dissection (11). 
Cryptogenic stroke was defined as those patients who had no other 
obvious cause for their stroke after an evaluation by neurology which 
included medical history, a brain MRI, evaluation of the carotid arteries 
and aortic arch, cardiac evaluation by transthoracic or transesophageal 
echocardiography, and monitoring for arrhythmias such as atrial 
fibrillation. A migraine diagnosis was identified by reviewing the 
neurology notes in the electronic medical record. A migraine with 
frequent aura diagnosis was defined in individuals experiencing aura in 
at least 50% of migraine attacks. A PFO with RLS diagnosis was identified
by the presence of a positive bubble contrast study with either 
transthoracic echocardiography (TTE), transesophageal 
echocardiography (TEE), or transcranial Doppler (TCD). TCD has been 
demonstrated to have higher sensitivity for detection of RLS when 
compared to contrast transesophageal echocardiography and is superior 
to transthoracic echocardiography (12, 13). It is important to note that 
although the TCD exam reveals the presence of a RLS, it does not 
distinguish between a PFO and PAVM. However, in our experience of 
1500 TCDs the rate of PAVM is only 1% in patients referred without 
hereditary hemorrhagic telangiectasia (Tobis, unpublished data, 2017); 
similar results have been demonstrated in the literature and thus a 
positive RLS exam was used to define the prevalence of PFO (14, 15). 
Using passage of a guide wire across the atrial septum during cardiac 
catheterization with intracardiac echocardiography guidance as the 
standard for diagnosing a PFO, TCD ≥ grade 3 has 98% sensitivity for 
making the diagnosis of PFO (16). The degree of RLS was evaluated by 
TCD at rest and with the Valsalva maneuver. The Spencer logarithmic 
scale was used to grade the results, a grade of 2 or higher (> 10 embolic
tracks/60 sec) was considered positive for a significant shunt, which has 
a 97% sensitivity and 100% specificity for the diagnosis of PFO (12).
Comparisons in PFO prevalence were made between patients with 
cryptogenic stroke without migraine, cryptogenic stroke with migraine, 
and cryptogenic stroke with migraine with aura using Fisher’s exact test. 
PFO prevalence in patients with cryptogenic stroke was compared to 
estimates of PFO in the general population. After identifying patients with
both migraine and stroke, the frequency of a diagnosis of migrainous 
infarction was investigated. A migrainous infarction was defined as a 
typical migraine for that patient that begins with aura or their usual 
cephalgic pain but progresses into a clinical stroke that is documented 
with a lesion on brain MRI (10, 17).
RESULT
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 of age were identified in the stroke database of the UCLA 
Comprehensive Stroke Center from January 1, 2008 to November 1, 
2017. The upper age limit was set at 60 years as part of the definition of 
cryptogenic stroke. The stroke types were divided into ischemic 
712/1255 (57%), intracerebral hemorrhage 293/1255 (23%), 
subarachnoid hemorrhage 183/1255 (15%) and transient ischemic 
attack 67/1255 (5%). Based on ASCOD phenotyping (11), the cause of 
the 712 ischemic strokes were further divided into the following 
categories: atherosclerosis 151/712 (21%), small artery disease 51/712 
(7%), cardiac (other than PFO) 165/712 (23%), other 105/712 (15%)
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and dissection 113/712 (16%). The remainder of the cases were 
considered cryptogenic in 127 of the 712 ischemic strokes (18%) 
(Figure 1).
Of the 127 patients with cryptogenic stroke, 68 (54%) had adequate 
testing to determine the presence of a PFO with RLS (by contrast TTE, 
TEE, or TCD) and a complete migraine history. Of the 68 cryptogenic 
stroke patients who had adequate testing for the presence of a RLS, 47 
of 68 (69%) had a PFO. PFO with RLS was identified in 8 patients (17%) 
via TTE, 16 patients (34%) via TEE, 6 patients (13%) via TCD, and 17 
patients (36%) via both TEE and TCD. All of the patients diagnosed via 
TCD had shunts that were Spencer grade 2 or greater.
Of the 68 cryptogenic stroke patients who had adequate testing for the 
presence of a RLS, 34 (50%) had migraine; and 15 of these 34 (44%) 
migraine patients had frequent aura (Figure 2). Of the 34 patients who 
had cryptogenic stroke and migraine, 27 (79%) had a PFO and of the 34 
patients with cryptogenic stroke who did not have migraine, 20 (59%) 
had a PFO. Moreover, of the 15 patients with both cryptogenic stroke and 
migraine with frequent aura, 14 (93%) had a PFO (Figure 3). The 
difference in prevalence of PFO between patients with cryptogenic stroke 
without migraine, with migraine, and with migraine with aura was 
statistically significant (p = 0.042).
When compared to a control general population of 200 people where the
prevalence of PFO was 18% as determined by a TCD ≥ grade 3, patients 
with cryptogenic stroke with or without migraine had significantly 
greater prevalence of PFO (χ2, p < 0.00001 and χ2, p < 0.00001, 
respectively)(18).
Five of the 128 (4%) patients who had cryptogenic stroke presented 
with a history that was compatible with a migrainous infarction. All 5 of 
these patients had a prior history of migraine. Two of the 5 (40%) 
patients with possible migrainous infarction had a PFO.
DISCUSSION
Our results from a database of all subjects who presented with a stroke 
to one academic medical center demonstrate a high prevalence of PFO 
(69%) in patients with cryptogenic stroke. Prior studies showed estimates
of PFO in the cryptogenic stroke population between 38% and 48%, with 
slight differences based on patient age (19). Only transthoracic 
echocardiography was used to detect abnormalities in the atrial septum 
in these groups of patients, and thus a significant number of PFOs may 
have been missed. A subsequent meta- analysis found a broader range in
the incidence of PFO in the cryptogenic stroke population, between 31% 
and 77%; these differences were largely attributed to differences in 
detection technique (20).
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Additionally, our results show a high prevalence of migraine (50%) in 
patients with cryptogenic stroke. These results corroborate the findings 
of a study which demonstrated that migraine increased the odds of 
cryptogenic events, both TIA and stroke, with an odds ratio of 1.73 (95%
confidence interval 1.38 – 2.16) relative to those without 
migraine(21).This effect may reflect an underlying association of both 
migraine and cryptogenic stroke with PFO (22).
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The literature is mixed regarding the relationship between migraine and 
PFO. One large study did not find a significant association between PFO 
and increased prevalence of migraine (odds ratio 1.01, 95% confidence 
interval 0.63–1.61) or migraine with aura (odds ratio 1.01, 95% 
confidence interval 0.71–1.69) (23). It should be noted that this study 
excluded patients with a history of stroke. A meta-analysis, which did 
include patients with a history of stroke, found a significant bidirectional 
relationship between PFO and migraine (24): The prevalence of migraine
in patients with PFO relative to those without PFO was characterized by 
an odds ratio of 5.13 (95% confidence interval 4.67 – 5.59), with 
significant results for the subgroup of patients who had migraine with 
aura; the prevalence of PFO in patients with migraine relative to those 
without migraine, independent of aura, was characterized by an odds 
ratio of 2.54 (95% confidence interval 2.01 – 3.08). These differences in 
the literature may be related to the inclusion of stroke patients in the 
study population, and what has been described as a “triad” of 
cryptogenic stroke, patent foramen ovale, and migraine with aura.
Wilmshurst, et. al. was the first to report that there was a high 
association of PFO in migraineurs who developed a stroke (5). In his 
study of 60 patients who presented with a stroke and had a history of 
migraine with aura, 84% had evidence of a PFO with a RLS. In our study, 
patients with both cryptogenic stroke and migraine had a high 
prevalence of PFO (79%), which is similar to the frequency that was 
reported by Wilmshurst. In the subset of patients with cryptogenic stroke
who had migraine with frequent aura, the prevalence of PFO was also 
very high (93%). One explanation for this observation is that migraine 
with frequent aura may be a marker for the presence of PFO (25). The 
prevalence of PFO in patients with cryptogenic stroke without migraine 
was also elevated (59%), and the prevalence of PFO in each group was 
significantly higher than in a general population of 200 subjects at UCLA 
(18%) (18).
Many studies have highlighted the association between migraine with 
aura and PFO (24, 26, 27). The PREMIUM trial prospectively randomized 
230 patients with PFO and medically- refractory migraine (with or without
aura) to PFO closure versus a sham procedure.
Although the primary endpoint of 50% reduction of migraine attacks was 
not met, there was a significant reduction in mean headache days per 
month (−3.4 ± 4.4 days per month in the PFO closure arm versus −2.0 ±
5.0 days per month in the sham procedure arm, p=0.03) and a strong 
treatment response for the subgroup who had migraine with frequent 
aura (49% responded in the PFO closure group versus 23% in the sham 
procedure group, p=0.015,withresponse defined as at least a 50% 
reduction in migraine attacks per month) (28). Moreover, in all 
migraineurs, complete remission occurred in 8.5% of the closure group, 
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compared with only 1% of the sham group (p=0.01), suggesting that PFO
may be causally related in some migraineurs.
The mechanism of migraine reduction via PFO closure is not entirely 
clear, though the association with cryptogenic stroke may provide 
insight into this relationship. Several theories have been proposed on 
the relationship between migraine and PFO due to right-to- left shunting 
of blood. Chemical triggers of migraine that are normally metabolized in 
the lung could bypass the pulmonary circulation through a PFO and 
thereby enter the cerebral circulation in higher concentrations. 
Alternatively, deoxygenated venous blood entering the
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arterial system through a PFO could be sufficient to trigger a 
migraine in susceptible individuals (29, 30).
There is also evidence to suggest that release of platelet serotonin may 
play a role in the development of migraine in patients with RLS. It has 
been proposed that platelets, as a result of sheer stress, may become 
activated and release serotonin, ultimately leading to migraine; this 
process may be initiated by cardiovascular abnormalities, such as PFO 
(31, 32). There is also data that mitral valve prolapse (MVP) may similarly
be implicated in migraine pathophysiology. It has been proposed that 
platelet damage from the mitral valve regurgitant jet could induce 
platelet damage and lead to release of serotonin (32). Interestingly, data 
has shown a significantly higher prevalence of MVP in patients with 
migraine versus control patients, with an odds ratio of 2.7 (95% CI 1.17 
and 6.29) (33).
Microemboli have also been proposed as a migraine trigger. Small 
venous blood clots or platelet aggregates, which normally would be 
trapped by the lungs (and thus remain clinically silent), may act as a 
potential trigger for migraine when introduced into the arterial circulation
through a right-to-left shunt (34, 35). Animal experiments support this 
hypothesis; mircoemboli have been shown to trigger cortical spreading 
depression (CSD), the slow cerebral depolarization underlying migraine 
with aura (36). Moreover, this theory of paradoxical microembolism 
provides a direct connection between PFO, migraine, and stroke, as 
larger emboli could attain a sufficient threshold of cerebral ischemia to 
produce an infarct.
Although more studies are needed to further elucidate these various 
theories, the relationship between stroke and migraine is unlikely to be 
explained primarily by vasoconstriction leading to infarction. Previous 
radiopharmaceutical scans have shown that cerebral blood flow only 
decreases by 25% from baseline during migraine, which would not be 
sufficient to cause tissue necrosis (9). Instead, the significant association 
between cryptogenic stroke, migraine, and PFO suggests that stroke in 
migraineurs may be mediated by a PFO pathway in the majority of cases. 
Our data support this latter hypothesis as the majority of patients in our 
study had overlap of cryptogenic stroke, migraine, and PFO but only 3 
patients had a presentation consistent with migrainous infarction without 
the presence of a RLS.
Our results were limited by the adequacy of testing for PFO, and the 
selection bias inherent in a cohort of patients who underwent more 
thorough testing for RLS. Patients are often recommended for a TTE with
bubble study to rule out PFO. Even at the UCLA Stroke Center of 
Excellence, in which stroke etiology is extensively investigated in all 
patients, TTE with bubble study was often the primary imaging modality 
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ordered, especially in the earlier years of this database. This can 
produce false negative results in over 50% of cases, as evidenced by a 
meta-analysis which included over 3,000 patients (37). In our study 
population, only 54% of patients with cryptogenic stroke had both 
sufficient PFO testing and a complete migraine history performed. It is 
possible that many patients had PFOs that went undiagnosed. These 
data suggest that when an etiology for stroke is not identified, prior to 
classifying a patient as cryptogenic, a TEE or TCD with agitated saline 
contrast should be obtained. This becomes particularly important in 
patients with a history of migraine, especially if they also experience 
aura. It should be emphasized that TCD saline
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studies are not only more predictive than TEE for detection of RLS but 
also more predictive of recurrent events (38). Moreover, TEE misses 15%
of RLS detected with TCD saline studies, and large shunts on TCD predict
recurrent stroke better than the presence of a shunt on TEE (38).
The value of obtaining a thorough headache history in patients who 
present with cryptogenic stroke should be emphasized; a simple 
headache questionnaire, such as the Migraine Prevention Questionnaire 5
(MPQ-5), can be used for this purpose (39). Physicians must also be 
mindful of important clinical clues that are suggestive of paradoxical 
embolism in patients with cryptogenic stroke. Data have shown that 
individuals with paradoxical embolism are more likely to present with 
dyspnea or a Valsalva maneuver at the onset of stroke, waking up with 
stroke, a history of deep vein thrombosis, pulmonary embolism or the 
presence of varicose veins, or a history of sleep apnea(40).
The ultimate test for whether a PFO is present is not an agitated saline 
bubble study, but is a right heart catheterization with a guidewire to 
probe the atrial septum under intra-cardiac echo imaging or injection of 
contrast against the foramen ovale. In those patients who had a stroke 
and a history of migraine but do not have a positive study demonstrating
a RLS, misdiagnosis is one possible explanation; migrainous stroke is 
another explanation, but if a PFO is not present, the etiology in these 
cases is truly cryptogenic.
Our results were also limited by a migraine diagnosis that was made 
without the consistent use of formal International Classification of 
Headache Disorders (ICHD) criteria (41).
Previous studies have found, however, that patient or physician-identified
migraine is corroborated by ICHD criteria in the overwhelming majority of
cases, such that the accuracy of diagnosis in our study is likely to be high
(42). Nonetheless, migraine may be under- reported in our study based 
on lack of patient or physician reporting.
Another limitation of this study is its retrospective, observational nature 
without a comparison group, and the biases inherent in this design. 
Moreover, the associations we found do not prove causality; instead they
are hypothesis generating and highlight relationships that exist between 
cryptogenic stroke, migraine, and PFO. The original Wilmshurst study 
that identified an increased incidence of PFO in migraineurs who 
developed a stroke focused on patients that were referred specifically for
workup for paradoxical embolism (5). Our study instead started with a 
large, heterogeneous database of all stroke patients and then 
retrospectively identified those with migraine who were tested for a PFO.
This strengthens the generalizability of the results in that this cohort 
represents the entirety of the stroke population at one referral institution
and emphasizes the high incidence of undiagnosed PFO and migraine in 
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this group. Future studies should continue to target this population and 
further elucidate relationships in the triad of stroke, migraine, and PFO.
The current stroke classification scheme does not include a separate 
category for PFO. The “cardiac” subcategory that does exist excludes 
PFO and is reserved for clot originating on the left side of the heart. 
Based on our results of the high degree to which PFO is implicated in 
patients currently classified as “cryptogenic,” future stroke classification 
schemes should
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consider including PFO as a separate etiologic category. If there is a 
stroke without an obvious ASCOD etiology but a PFO is present, it is no 
longer sufficient to define this as "cryptogenic", but could be 
categorized as a "PFO-associated stroke". Further support for having a 
PFO-associated stroke as a separate etiologic category comes from the 
RESPECT and REDUCE randomized trials, which demonstrated a 
significant reduction in recurrent stroke for subjects who had their PFO 
closed percutaneously: HR = 0.55 (95% CI 0.31 to 0.999; p = 0.046) 
and RR = 0.51 (95% CI, 0.29 to 0.91; P = 0.04), respectively, which 
provides evidence that PFO is causally related to cryptogenic stroke (43,
44).
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Figure 1.
Flow Chart for Patient Selection
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Figure 2.
Flow Chart for Patient Selection
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Figure 3.
Prevalence of PFO in Patients with Cryptogenic Stroke
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